The intestinal barrier function relies on the presence of a single layer of epithelial cells that selectively absorb nutrients and water while limiting intestinal content and gut microbiota into the lumen. When epithelial barrier function is compromised, unregulated translocation of microbiota and microbial products into the mucosa can result in intestinal inflammation as seen in IBD patients. Effective resolution of inflammation requires elimination of inflammatory triggers and this is partly dependant on epithelial wound healing. The intestine is constantly exposed to proteases originating from a variety of sources and these proteases can activate protease-activated receptors (PARs). The mechanism of intestinal epithelial wound healing is not completely understood, particularly in the context of proteases and PARs. It was recently shown that PAR2 activation transactivates epidermal growth factor receptor (EGFR) and also induces COX-2 expression in colonic epithelial cells. Based on this, it was hypothesized that PAR2-induced EGFR transactivation and COX-2 expression drive colonic epithelial wound healing. In the first part of the study, CMT-93 cells were characterized for PAR2 expression and PAR-2 induced COX-2 expression. PAR2 is primarily expressed in the plasma membrane with punctate immunoreactivity in the cytoplasm. Furthermore, the majority of PAR2 expression appeared to be basolateral. PAR2 activation by 2fLI (2-furoyl-LIGRLO-NH2) induced Ca2+ signaling. COX-2 expression was characterized using western blotting and PAR2 activation did not induce COX-2 expression in CMT93 cells. The effect of PAR2 activation in wound healing was investigated in the second part of the study. PAR2 activation induced wound healing and the treatment with the COX-2 selective inhibitor (NS-398) did not affect the PAR-2 induced wound healing, indicating that PAR-2 induced wound healing does not depend on COX-2 activity. The treatments with the EGFR tyrosine kinase inhibitor (PD153035), broad-spectrum matrix metalloproteases (MMP) inhibitor (GM6001) or Src tyrosine kinase inhibitor (PP2) inhibited PAR2-induced wound healing. These results suggest EGFR activity is required for PAR2-induced wound healing and PAR2 activation possibly transactivates EGFR via-matrix metalloproteinases and Src tyrosine kinase activity. In conclusion, this study shows the contribution of PAR-2 in epithelial wound healing, which could subsequently aid in the resolution of intestinal inflammation.